Table of Content

Open Access Original Research

Taste Impairment and Compliance Improvement of Branched-Chain Amino Acids in Patients with Liver Cirrhosis

Received: 25 September 2018;  Published: 26 December 2018;  doi: 10.21926/obm.hg.1804011

Abstract

Background: Branched-chain amino acids (BCAA) are nutrients with a bitter taste, which causes low compliance in patients who need BCAA supplementation. Moreover, chronic liver disease is frequently complicated by taste impairment. The present study was designed to improve patient noncompliance regarding nutrients in liver disease. Methods: A taste questionnaire was administered to healthy controls, chronic hepatitis patients, and cirrhotic patients. Eleven different flavored powders that can be added to BCAA nutri [...]

1130 5027

Open Access Communication

Gut Microbes and Pathophysiology of Sepsis: Spillage of Gut Microbial Products, rather than Systemic Dissemination of Gut Microbes, is the Potential Initiator of Septic Morbidity

Received: 22 July 2018;  Published: 09 September 2018;  doi: 10.21926/obm.hg.1803010

Abstract

Gut microbes and pathophysiology of sepsis: Spillage of gut microbial products, rather than systemic dissemination of gut microbes, is the potential initiator of septic morbidity

1027 5216

Open Access Case Report

An Unusual Case of Signet Ring Cell Cholangiocarcinoma: Case Report and a Review of Literature

Received: 17 February 2018;  Published: 01 September 2018;  doi: 10.21926/obm.hg.1803009

Abstract

Cholangiocarcinoma is an uncommon adenocarcinoma with poor prognosis. Signet ring cell cholangiocarcinoma is an extremely rare disease, with only 11 cases reported to date. However, its incidence is increasing. Similarly, there is an increasing incidence of other SRC tumors (colon, gastric etc.) as well. Most cases have described a localized mass of signet ring cells, mostly in the common bile duct. A 69-year-old Caucasian man admitted for jaundice and abdominal pain that began 3 days prior to his hospitalization. [...]

1071 6170

Open Access Original Research

Peptides Obtained by Enzymatic Decomposition of Mackerel Prevent Nonalcoholic Steatohepatitis in Sprague-Dawley Rats fed a High-fat and High-cholesterol Diet

Received: 09 April 2018;  Published: 03 August 2018;  doi: 10.21926/obm.hg.1803008

Abstract

Background: The pathogenesis of nonalcoholic steatohepatitis (NASH) is thought to be multifactorial, and oxidative stress may play an important role in the development of NASH. Peptides obtained by enzymatic decomposition of mackerel (EMP) including selenoneine were recently reported to possess antioxidative activity. Thus, EMP can be a candidate dietary strategy for the prevention of NASH. [...]

1169 5779

Open Access Review

Models for Predicting Risk of Acute Kidney Injury after Liver Surgery

Received: 05 February 2018;  Published: 16 May 2018;  doi: 10.21926/obm.hg.1802007

Abstract

Background & Aims. Acute kidney injury (AKI) is a serious complication of liver surgery and associated with significant morbidity and mortality. The incidence of AKI following hepatic surgery can be as high as 94%, with highest rates seen following orthotopic liver transplantation, particularly when extended criteria grafts are used. Strategies to identify patients at risk of AKI may enable early interventions to prevent or minimise AKI. Methods. A systematic review was conducted using PubMed, Medline, Cochrane and [...]

1302 5689

Open Access Original Research

Misinterpretation or Underestimation of the Appearance, Location, or Size of Non-bleeding Visible Vessels (Forrest Class IIa) as a Cause of Hemostasis Failure

Received: 10 December 2017;  Published: 14 March 2018;  doi: 10.21926/obm.hg.1801006

Abstract

(1) Background: Endoscopy has become the primary diagnostic and treatment technique for non-variceal upper gastrointestinal bleeding. Despite advancements in therapeutic methods and instrumentation, endoscopic hemostatic failure occurs in 10% of patients. This study aimed to analyze endoscopic findings in patients with failed hemostasis and to elucidate strategies for endoscopists and gastroenterologists to facilitate improved treatment outcomes. (2) Methods: A total of 128 patients received hemostatic treatment fo [...]

1161 8292

Open Access Editorial

Anemia during Direct-Acting Antiviral Regimens in Kidney Transplant Recipients with Hepatitis C

Received: 18 October 2017;  Published: 29 October 2017;  doi: 10.21926/obm.hg.1704005

Abstract

(This is review and no abstract)

1163 4981

Open Access Case Report

Successful Treatment of a Pregnant Woman with Chronic Active Hepatitis B using Tenofovir Disoproxil Fumarate

Received: 23 June 2017;  Published: 27 July 2017;  doi: 10.21926/obm.hg.1703004

Abstract

(1) Background: Infection with hepatitis B virus (HBV) infection during pregnancy occasionally raises concerns, including acute exacerbation and the potential for mother-to-child transmission. (2) Case Report: Here, we present a case of a female patient with a chronic HBV infection who was treated with tenofovir disoproxil fumarate (TDF) and had a normal pregnancy and delivery. Furthermore, the use of TDF, HBV vaccination and passive immunization of her child with hyperimmune hepatitis B immunoglobulin successfully [...]

883 5335

Open Access Original Research

IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients

Received: 08 February 2017;  Published: 06 April 2017;  doi: 10.21926/obm.hg.1702003

Abstract

Background: Hepatitis C virus (HCV) infection frequently occurs in recipients of liver or kidney transplants (LT/KT). Interferon (IFN)-based therapies are used to treat HCV, but their efficacy is low. Methods: We report 24 patients who received HCV therapy after LT/KT. Design, Setting, and Participants-Twelve LT and 12 KT recipients (median age, 59 years; 15 males; 21 serological type 1) were enrolled, of whom eight (six with LT) were treated with IFN-based therapy. Twelve received direct-acting antiviral drugs [ [...]

964 6179

Open Access Editorial

Response-Guided Treatment with an Ultrarapid Virological Response Creates the Future of Interferon-Free Treatment against Hepatitis C

Received: 22 January 2017;  Published: 03 February 2017;  doi: 10.21926/obm.hg.1701002

968 4521

TOP